KRAS and non-small cell lung carcinoma: (117) claimed that patients with KRAS G12C rearrangement developed significantly more bone metastases compared with those in the control group of the cohort (59% vs. 16%, respectively; p<0.0001) after thoracic surgery for NSCLC.